These increases in CB NK subsets were in part secondary to augmentation of cell survival.
Misclassification of the primary or secondary outcomes (augmentation, switch, and discontinuation) may have also occurred; however, medication dispensings are generally reliable administrative data because they require reimbursement by the health plans.
Secondary outcomes were: augmentation of labour, pain relief, and postpartum haemorrhage, and neonatal outcomes measured by an Apgar score <7 at 5 minutes, metabolic acidosis defined as an umbilical artery pH <7.05 and BE (Base Excess) <−12 mmol/l, 24 and transfers to the neonatal intensive care unit (NICU).
Secondary outcome measures include augmentation index, peripheral and central blood pressures, physical activity and self-reported health.
It is expected that this technique may be effectively utilized for a secondary operation after submuscular breast augmentation.
Secondary end points were change in augmentation index (measured during PWA), PWV, and blood markers.
It is hoped that this will result in improvements in health care, through safer and more effective prescribing, augmentation of primary and secondary prevention strategies, and enhanced understanding of the biology of disease.
Secondary objectives were to evaluate whether certain augmentation procedures or materials may be advantageous in terms of implant survival.
These data suggest that patients with secondary RLS are less likely to develop augmentation than those with primary RLS.
However, olanzapine augmentation did significantly improve the secondary outcome measure sleep continuity, that included sleep efficiency, number of awakenings, time spent awake and total sleep time.
